RNA pulldown 实验表明,CBR3-AS1 可以直接结合 miR-25-3p(图 f-g)。RT-PCR 和 WB 实验显示,在 MCF-7 细胞中过表达 CBR3-AS1 可以显著提高 JNK1 和 MEK4 的表达(图 i-j),而 MCF-7/ADR 细胞中沉默 CBR3-AS1 则会下调 JNK1 和 MEK4 的表达(图 k-l)。 综上所述,CBR3-AS1 可以通过 miR-2...
RNA pulldown 实验表明,CBR3-AS1 可以直接结合 miR-25-3p(图 f-g)。RT-PCR 和 WB 实验显示,在 MCF-7 细胞中过表达 CBR3-AS1 可以显著提高 JNK1 和 MEK4 的表达(图 i-j),而 MCF-7/ADR 细胞中沉默 CBR3-AS1 则会下调 JNK1 和 MEK4 的表达(图 k-l)。 综上所述,CBR3-AS1 可以通过 miR-2...
CBR3-AS1沉默序列(沉默组),用MTT实验与Transwell实验检测各组细胞的增殖与侵袭能力.结果:lncRNA CBR3-AS1的表达在胆管癌组织中明显高于癌旁组织,在胆管癌细胞系中明显高于正常胆管上皮细胞(均P<0.01).lncRNA CBR3-AS1表达与CCA患者淋巴结转移,TNM分期和术后复发明显有关(P<0.05).lncRNA CBR3-AS1高表达患者...
9. (3+1)维广义破缺孤子系统的XXX多异常波、双周期孤子和呼吸波解(数学) 10. 关于CBR3-AS1在人类恶性肿瘤中XXX致癌功能的思考:从分子调控机制到临床应用(医学,生物) 11. 应用门控循环单元网络和XXX新型旗鱼优化器在宫颈癌细胞诊断中的应用(医学,计算机) ...
2021 年 1 月,中国医科大学药学院高华、魏敏杰教授和赵琳教授为共同通讯作者,在 Journal of Experimental & Clinical Cancer Research (IF: 11.161) 杂志发表了题为“LncRNA CBR3-AS1 regulates of breast cancer drug sensitivity as a competing endogenous RNA through the JNK1/MEK4-mediated MAPK signal pathway...
5p表达对鼻咽癌细胞的增殖与侵袭的抑制作用(P<0.05).小鼠移植瘤实验显示,下调lncRNA CBR3-AS1表达可上调miR-145-5p表达,从而下调FSCN1表达,抑制鼻咽癌移植瘤的生长(P<0.05).lncRNA CBR3-AS1在鼻咽癌组织中上调表达,下调lncRNA CBR3-AS1表达可通过调控miR-145-5p/FSCN1轴抑制鼻咽癌细胞的增殖与侵袭,促进细胞凋亡...
目的探讨长链非编码RNA(lncRNA)CBR3-AS1通过PI3K/AKT/mTOR/S6K通路介导急性髓细胞白血病(AML)细胞对阿糖胞苷耐药的可能机制.方法在2个AML细胞株K562和HL-60中建立耐药模型,分别为K562-R和HL-60-R.逆转录-实时定量聚合酶链反应(RT-qPCR)法检测lncRNA CBR3-AS1在K562-R和HL-60-R中的表达情况.在K5...
CBR3-AS1 was up-regulated in MDA-MB-231 compared with ANCTs. AR was significantly down-regulated in both breast cancer cell lines compared with ANCTs. AR expression was lower in tumoral tissues compared with ANCTs but it did not reach the level of significance. CBR3-AS1 expression has ...
CBR3-AS1 also promoted tumor growth in vivo. CBR3-AS1 may regulate the expression and functions of the miR-409-3p target gene SOD1. CBR3-AS1 expression was negatively correlated with radiosensitivity. CBR3-AS1 downregulation decreased post-irradiation SOD1 expression, increased 纬H2AX formation, ...
CBR3-AS1miR-25-3pMAPK signaling pathwayBackground Adriamycin (ADR) resistance is one of the main obstacles to improving the clinical prognosis of breast cancer patients. Long noncoding RNAs (lncRNAs) can regulate cell behavior, but the role of these RNAs in the anti-ADR activity of breast ...